From Name

From Email

To Name

To Email

Message

FDA approves belantamab in R/R multiple myeloma

from Medscape

FDA approves belantamab in R/R multiple myeloma Medscape The first-in-class drug belantamab mafodotin has been granted an accelerated approval by the U.S. Food and Drug Administration for use in the treatment of relapsed and refractory multiple myeloma in patients who have already tried other therapies. READ MORE

more